Intimation of incorporation of a new wholly owned subsidiary in USA.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Aurobindo Pharma has set up a new wholly owned subsidiary in the USA called Cresedemo Pharma LLC, incorporated on June 13, 2025. The new entity was created through Aurobindo Pharma USA Inc, which is already a wholly owned subsidiary of the company. The purpose is to expand Aurobindo's pharmaceutical products business in the US market. Initial capital is modest at USD 10,000 (10,000 shares at USD 1 each), and no government or regulatory approvals were needed.

Likely market impact

This is a routine corporate expansion move to strengthen the company's US presence. The very small initial capital (USD 10,000) suggests early-stage setup rather than a major investment, so no immediate material impact on shareholders is expected.